Marketplace®

Daily business news and economic stories

Helen Palmer

Latest from Helen Palmer

  • Stung by criticism of how it handled Hurricane Katrina and the 9/11 attacks, the American Red Cross today announced plans for a major overhaul that includes slashing its 50-member board. Helen Palmer reports.

    Read More
  • Merck's arthritis drug Vioxx is back in court today as an 11th case goes to trial, but the legal landscape of the ongoing litigation has changed considerably. Helen Palmer reports.

    Read More
  • A new test appears to be 80% accurate in predicting which drugs would be most effective in treating a particular patient's cancer. Is it the next big breakthrough? Helen Palmer reports.

    Read More
  • About 46 million Americans don't have health insurance. Some states have stopped waiting on the federal government and put universal health care measures on their ballots. Leading the way: Massachusetts. Helen Palmer reports.

    Read More
  • Pharmaceutical giant Pfizer has made a relatively small purchase with some big implications. Helen Palmer explains why buying a small British vaccine company could be a shrewd move.

    Read More
  • It's still illegal to import them, but starting next week U.S. Customs agents will no longer routinely seize packages of prescription drugs arriving by mail from Canada. Helen Palmer reports.

    Read More
  • When Medicare launched its new drug benefit a year ago, critics predicted horror story scenarios. But new details released by the Bush administration have Medicare officials doing a victory dance. Helen Palmer reports.

    Read More
  • Doctors and manufactures are lobbying health regulators to discontinue use of the word "recall" when issuing advisories on faulty heart devices. Helen Palmer reports.

    Read More
  • The world's largest retailer opened its first store in Chicago yesterday, advancing a strategy to try to cash in on urban hipsters. But being the low-cost leader doesn't guarantee success, Helen Palmer reports.

    Read More
  • Many in the food and pharmaceutical industries support reforming the FDA. Their bottom lines are very much at stake, Helen Palmer reports.

    Read More